Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. 2020

Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
Department of Advanced Sciences and Technologies in Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran; Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.

The emergence of the global pandemic caused by the novel SARS-CoV-2 virus has motivated scientists to find a definitive treatment or a vaccine against it in the shortest possible time. Current efforts towards this goal remain fruitless without a full understanding of the behavior of the virus and its adaptor proteins. This review provides an overview of the biological properties, functional mechanisms, and molecular components of SARS-CoV-2, along with investigational therapeutic and preventive approaches for this virus. Since the proteolytic cleavage of the S protein is critical for virus penetration into cells, a set of drugs, such as chloroquine, hydroxychloroquine, camostat mesylate have been tested in clinical trials to suppress this event. In addition to angiotensin-converting enzyme 2, the role of CD147 in the viral entrance has also been proposed. Mepolizumab has shown to be effective in blocking the virus's cellular entrance. Antiviral drugs, such as remdesivir, ritonavir, oseltamivir, darunavir, lopinavir, zanamivir, peramivir, and oseltamivir, have also been tested as treatments for COVID-19. Regarding preventive vaccines, the whole virus, vectors, nucleic acids, and structural subunits have been suggested for vaccine development. Mesenchymal stem cells and natural killer cells could also be used against SARS-CoV-2. All the above-mentioned strategies, as well as the role of nanomedicine for the diagnosis and treatment of SARS-CoV-2 infection, have been discussed in this review.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral

Related Publications

Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
November 2021, Viruses,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
January 2020, Frontiers in veterinary science,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
June 2023, Clinical and experimental medicine,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
April 2021, Stem cell research,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
June 2021, Acta medica portuguesa,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
May 2022, Life (Basel, Switzerland),
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
December 2023, Nature aging,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
August 2023, Nature,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
January 2021, Journal of molecular biology,
Fatemeh Oroojalian, and Ali Haghbin, and Behzad Baradaran, and Nima Hemmat, and Mohammad-Ali Shahbazi, and Hossein Bannazadeh Baghi, and Ahad Mokhtarzadeh, and Michael R Hamblin
October 2021, Intestinal research,
Copied contents to your clipboard!